Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard sold 1,828 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $35.10, for a total transaction of $64,162.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 0.09% during mid-day trading on Tuesday, hitting $34.56. The stock had a trading volume of 129,903 shares. KYTHERA Biopharmaceuticals has a one year low of $23.03 and a one year high of $56.36. The stock has a 50-day moving average of $35.77 and a 200-day moving average of $38.98. The company’s market cap is $783.0 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $2.51. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Receive News & Ratings for KYTHERA Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KYTHERA Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.